IN2014DN05772A - - Google Patents

Info

Publication number
IN2014DN05772A
IN2014DN05772A IN5772DEN2014A IN2014DN05772A IN 2014DN05772 A IN2014DN05772 A IN 2014DN05772A IN 5772DEN2014 A IN5772DEN2014 A IN 5772DEN2014A IN 2014DN05772 A IN2014DN05772 A IN 2014DN05772A
Authority
IN
India
Prior art keywords
galectin
medicament
novel compounds
compounds
ligandsin
Prior art date
Application number
Inventor
Ulf Nilsson
Hakon Leffler
Balaram Mukhopadhyay
Vishal Rajput
Original Assignee
Galecto Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galecto Biotech Ab filed Critical Galecto Biotech Ab
Publication of IN2014DN05772A publication Critical patent/IN2014DN05772A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Abstract

The present invention relates to novel compounds prepared from readily accessible 3 O propargyl D galactopyranoside derivatives and having an effect as i.a. galectin inhibitors the use of said compounds as a medicament as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to ligandsin a mammal wherein said galectin is preferably a galectin 3. The novel compounds are defined by the general formula (I).
IN5772DEN2014 2012-01-25 2013-01-24 IN2014DN05772A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12152413.6A EP2620443A1 (en) 2012-01-25 2012-01-25 Novel galactoside inhibitors of galectins
PCT/EP2013/051339 WO2013110704A1 (en) 2012-01-25 2013-01-24 Novel galactoside inhibitors of galectins

Publications (1)

Publication Number Publication Date
IN2014DN05772A true IN2014DN05772A (en) 2015-04-10

Family

ID=47598867

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5772DEN2014 IN2014DN05772A (en) 2012-01-25 2013-01-24

Country Status (8)

Country Link
US (1) US9353141B2 (en)
EP (2) EP2620443A1 (en)
JP (1) JP6158840B2 (en)
CN (1) CN104066743B (en)
CA (1) CA2854986C (en)
ES (1) ES2559857T3 (en)
IN (1) IN2014DN05772A (en)
WO (1) WO2013110704A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
CA2389928C (en) 1999-11-03 2010-03-23 Bristol-Myers Squibb Company Method for treating diabetes
US9243021B2 (en) 2012-10-31 2016-01-26 Galecto Biotech Ab Galactoside inhibitor of galectins
CA2926480A1 (en) * 2012-11-15 2014-05-22 Tufts University Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor
JP2016507503A (en) 2012-12-20 2016-03-10 ヘンリー フォード ヘルス システム Method for treating diastolic heart failure by inhibiting galectin-3
US10253059B2 (en) 2014-07-09 2019-04-09 Galecto Biotech Ab Hybrid galactoside inhibitor of galectins
EP3250581B1 (en) * 2015-01-30 2021-01-20 Galecto Biotech AB Alpha-d-galactoside inhibitors of galectins
AU2017228365B2 (en) * 2016-03-04 2021-05-27 Galectin Sciences, Llc Selenogalactoside compounds for the prevention and treatment of diseases associated with galectin and the use thereof
CA3025867A1 (en) * 2016-07-12 2018-01-18 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
EP3484903A1 (en) * 2016-07-12 2019-05-22 Galecto Biotech AB Alpha-d-galactoside inhibitors of galectins
KR102626669B1 (en) 2017-05-12 2024-01-17 갈랙틴 사이언시즈, 엘엘씨 Compounds and their uses for the prevention and treatment of diseases
BR112020013198A2 (en) 2017-12-29 2020-12-01 Glycomimetics, Inc. heterobifunctional e-selectin and galectin-3 inhibitors
WO2020002765A1 (en) 2018-06-29 2020-01-02 Glykos Biomedical Oy Conjugates
EP3902797A1 (en) 2018-12-27 2021-11-03 GlycoMimetics, Inc. Galectin-3 inhibiting c-glycosides
WO2020139962A1 (en) 2018-12-27 2020-07-02 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
WO2021123506A1 (en) 2019-12-18 2021-06-24 Glykos Biomedical Oy Stabile conjugate

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100172D0 (en) 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
SE0401300D0 (en) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
SE0401301D0 (en) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors or galectins
CN103497228B (en) 2008-05-16 2016-08-10 格莱克特生物技术公司 The synthesis of galactoside inhibitor
EP2424873B1 (en) 2009-04-28 2017-11-15 Galecto Biotech AB Novel galactoside inhibitors of galectins
EP2914269B1 (en) 2012-10-31 2020-07-29 Galecto Biotech AB Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis

Also Published As

Publication number Publication date
CA2854986A1 (en) 2013-08-01
EP2807176A1 (en) 2014-12-03
CN104066743A (en) 2014-09-24
US20140336146A1 (en) 2014-11-13
EP2807176B1 (en) 2015-12-30
WO2013110704A1 (en) 2013-08-01
JP6158840B2 (en) 2017-07-05
CA2854986C (en) 2019-09-17
ES2559857T3 (en) 2016-02-16
JP2015504909A (en) 2015-02-16
EP2620443A1 (en) 2013-07-31
US9353141B2 (en) 2016-05-31
CN104066743B (en) 2016-04-06

Similar Documents

Publication Publication Date Title
IN2014DN05772A (en)
AU2012214029A8 (en) Rorgammat inhibitors
MD20140002A2 (en) Indazoles
MY160241A (en) 5-alkynyl-pyrimidines
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
PH12015501116A1 (en) New indanyloxydihydrobenzofuranylacetic acids
NZ603789A (en) Heteroaryl compounds and methods of use thereof
MX2013004491A (en) Boronates as arginase inhibitors.
PH12016500225A1 (en) Novel quinoline-substituted compound
EA024702B8 (en) Novel immunomodulator and anti inflammatory compounds
IN2014MN02459A (en)
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
PH12015500211B1 (en) 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
IN2015DN01151A (en)
MX2014004858A (en) Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated pathologies.
MX342924B (en) Novel disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases.
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MX340577B (en) Phosphoinositide 3-kinase inhibitor with a zinc binding moiety.
WO2012061754A3 (en) Compounds and methods for treating autoimmune diseases
MX2013011124A (en) Compounds for treatment of metabolic syndrome.
UA111628C2 (en) COMPOSITION FOR PLANT DISEASE AND ITS APPLICATION
MX2014002988A (en) Process and composition for inhibiting the polymerization of cyclopentadiene compounds.
MX349548B (en) Thienopyrimidine compounds.
TN2012000469A1 (en) Use of novel pan-cdk inhibitors for treating tumors
MX2015005312A (en) 1 h-indole-3-carboxamide derivatives and use thereof as p2y12 antagonists.